Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
The Metabolic Syndrome (MS) is a cluster of cardiometabolic risk factors, which include
abdominal obesity, hyperglycemia, dyslipidemia, and high blood pressure. MS is considered a
serious problem to health systems due to a current inability on implementing an effective
prevention and treatment program. In Mexico 73% of adult population suffers obesity or
overweight, this condition triggers the best studied pathophysiological mechanism; insulin
resistance, which in turn precedes the diagnosis of diabetes and cardiovascular disease, that
are the main cause of general mortality in Mexico, thus the prevention and timely treatment
of this condition are now a priority.
Actual pharmacological therapy is designed to control its components individually, however,
there are great interest in developing new therapeutic lines that improve more than one
component simultaneously and thereby increase the cost-benefit and effectiveness of the
therapy. Fucoxanthin is a functional element present in seaweed species. Several studies have
offered certain perspectives on its action mechanism and safety. The information available is
favorable for weight control in overweight subjects, but its activity in glucose levels,
lipid metabolism and blood pressure is inconsistent. It represents a natural option with
great interest in this research, since it could be a new, safe and effective therapy in the
MS.
The aim of this study is to evaluate the effect of fucoxanthin on the components of the MS,
insulin sensitivity and insulin secretion. The investigators hypothesis is that Fucoxanthin
modifies the components of the MS, insulin sensitivity and insulin secretion